Showing results (61-70 of 118) with videos related to

Sort By:
Pageof 12
Anticancer Research|August 30, 2022
Association Between Peripheral Neuropathy Induced by Oxaliplatin at First-line Chemotherapy and Efficacy of Paclitaxel at Second-line Chemotherapy in Patients With Advanced Gastric CancerHironori Fujii, Shiori Sadaka, Kanae Ajisawa, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|July 23, 2015
[Analysis of Pemetrexed Monotherapy in Advanced Non-Small Cell Lung Cancer Patients with Impaired Renal Function]Norihiko Funaguchi, Yasuhiro Nakajima, Daizo Kaito, et al.
Anticancer Research|January 25, 2023
Relationship Between Osimertinib Concentration and Clinical Response in Japanese Patients With Non-small Cell Lung CancerMizuki Yamazaki, Nao Komizo, Hirotoshi Iihara, et al.
Cancer Chemotherapy and Pharmacology|December 1, 2016
Successful afatinib treatment of advanced non-small-cell lung cancer patients undergoing hemodialysisHisao Imai, Kyoichi Kaira, Ichiro Naruse, et al.
Systematic and Applied Microbiology|January 9, 2007
The dnaJ gene as a novel phylogenetic marker for identification of Vibrio speciesPham Hong Nhung, Mohammad Monir Shah, Kiyofumi Ohkusu, et al.
Journal of Pharmaceutical Health Care and Sciences|April 26, 2024
Medication reconciliation by pharmacists for pre-admission patients improves patient safetyYunami Yamada, Ryo Kobayashi, Taishi Yamamoto, et al.
BMJ Open|March 3, 2022
Study protocol for a double-blind, comparative, randomised Japanese trial of triplet standard antiemetic therapies with or without 5 mg olanzapine to prevent chemotherapy-induced nausea and vomiting for patients with breast cancer treated with an anthracycline/cyclophosphamide regimen (JTOP-B)Rie Ozeki, Hirotoshi Iihara, Mototsugu Shimokawa, et al.
BMJ Open|July 7, 2019
Clinical trial protocol of doublet therapy and olanzapine for carboplatin-induced nausea and vomiting in patients with thoracic cancer: a multicentre phase II trialHirotoshi Iihara, Mototsugu Shimokawa, Takenobu Gomyo, et al.
Anticancer Research|November 1, 2023
Efficacy and Safety of Oxaliplatin-based Regimens as First-line Chemotherapy in Elderly Patients With Metastatic Colorectal CancerSeiji Yamamoto, Hironori Fujii, Kotaro Murayama, et al.
Anticancer Research|April 25, 2023
Emetogenicity and Risk Factors of Nausea and Vomiting in Patients With Metastatic Colorectal Cancer Receiving Trifluridine/Tipiracil and Bevacizumab ChemotherapySerika Matsuoka, Hironori Fujii, Hirotoshi Iihara, et al.
Pageof 12